Australia markets close in 6 minutes

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.01-0.07 (-1.38%)
At close: 04:00PM EST
5.04 +0.03 (+0.60%)
After hours: 08:00PM EST

Anavex Life Sciences Corp.

630 5th Avenue
20th Floor
New York, NY 10111
United States
844 689 3939
https://www.anavex.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees40

Key executives

NameTitlePayExercisedYear born
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.President, CEO, Secretary & Director828.25k3.2M1966
Ms. Sandra Boenisch CPA, CGAPrincipal Financial Officer & Treasurer194.36kN/A1981
Mr. Stephan Toutain M.B.A., M.S.Senior VP of Operations & COON/AN/A1966
Dr. Walter E. Kaufmann M.D.Chief Scientific OfficerN/AN/AN/A
Clint TomlinsonVP of CorporateN/AN/AN/A
Dr. Adebayo Laniyonu Ph.D.Senior Vice President of Nonclinical DevelopmentN/AN/AN/A
Dr. Edward R Hammond M.D., M.P.H., Ph.D.Chief Medical OfficerN/AN/AN/A
Dr. Kun Jin Ph.D.Head of BiostatisticsN/AN/AN/A
Mr. David Goldberger R.Ph.Senior Vice President of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Corporate governance

Anavex Life Sciences Corp.’s ISS governance QualityScore as of 1 February 2024 is 4. The pillar scores are Audit: 7; Board: 3; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.